Join NBTS’s campaign to raise awareness about the importance of biomarker testing and clinical trials for patients with brain tumors.
READ MORE
Let’s Talk About Oligodendroglioma While oligodendroglioma is a relatively rare brain tumor, accounting for 1.2% of all primary brain tumors, an estimated 14,950 Americans are living with this tumor and navigating the unique challenges of this disease. Let’s talk about what makes oligodendrogliomas different from other brain tumors and the difficulties people living with this tumor type and their […] March 28, 2025
New Brain Tumor Clinical Trials: April – October 2024 It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients. This report provides a summary of the studies that have recently opened or started recruiting since our last report for patients with a primary brain tumor. Follow the hyperlink for […] November 7, 2024
Updated: Exciting News for Patients with Grade 2 Oligodendroglioma and Astrocytoma UPDATED (August 6, 2024): The U.S. Food and Drug Administration (FDA) has approved vorasidenib (brand name: Voranigo) for the treatment of adult and pediatric patients 12 years of age and older with grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection. This is […] August 6, 2024
From Heartache to Hope: The Story Behind the Bob Burns Memorial 5K Kelly T. cheered on more than 100 runners at the 2023 Bob Burns Memorial 5K while holding up two giant number balloons to celebrate 10 years of her Fundraise Your Way event that she started in her father’s memory. Kelly’s father, Bob, was diagnosed with oligodendroglioma when she was 16. “He worked in construction until […] April 19, 2024
New Brain Tumor Clinical Trials: January – March 2024 It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients. This report provides a summary of the studies that have recently opened or started recruiting (January 1, 2024 – April 9, 2024) for patients with a primary brain tumor*. Follow […] April 12, 2024